Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sobi

- PMLiVE

Shire’s gene therapy candidate receives orphan drug status in the US

Investigational factor VIII treatment SHP654 is being developed for haemophilia

Sobi appoints Norbert Oppitz SVP, speciality care

He joins the rare disease pharma firm from BSN Medical

Roche Basel Switzerland

Roche wins FDA priority review for haemophilia A drug

Emicizumab prophylaxis could be approved early next year

- PMLiVE

Shire strikes bi-specific antibody deal with Novimmune

Pharma giant obtains licence for haemophilia A candidate

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

- PMLiVE

Sobi looks to real-world trial to push Elocta take-up

Aims to show haemophilia A treatment’s benefit to reimbursement authorities

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

- PMLiVE

Shire’s Dr Armin Reininger moves to Sobi

Appointed as senior vice president, head of global medical and scientific affairs

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

Roche Basel Switzerland

Roche’s haemophilia A drug hits targets in registration trial

Emicizumab from Japanese affiliate Chugai cleared a phase III trial

- PMLiVE

A healthy challenge

The EC’s Dr Vytenis Andriukaitis on Europe’s problems with health

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links